New safety and efficacy data in heavily pre-treated patients with metastatic colorectal cancer (CRC), from a Phase 1 study of ABBV-400, a next-generation, potential best-in-class c-Met directed ADC. Data from a first-in-human study of ABBV-706, a potential best-in-class SEZ6 directed ADC, in small cell lung cancer (SCLC), high-grade central nervous system (CNS) tumors and high-grade neuroendocrine neoplasms (NENs). Data from the primary analysis of the Phase 2 LUMINOSITY trial evaluating Telisotuzumab ved ...

For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower.Let’s get some of the bad stuff out of the way first. Biotech stocks – even the established players – can be volatile. A miss in the clinical process to commercialize a therapeutic could lead to significant losses. And there’s really no way of reliably forecasting such outcomes. Plus, the sector isn’t always known for delivering predictable financial performanc ...

AbbVie's returns haven't been great this year, but investors shouldn't overlook this promising growth stock.Nvidia (NVDA 2.57%) has been a great stock to own, and it could remain that way for long-term investors. However, the problem is that it's trading at nearly 40 times its future profits. At such a high valuation, it sets a high bar for the business and effectively prices in a lot of future growth already. It could make it difficult for the stock to continue to generate high returns. Even if it does, at ...

bunhill Written by Sam Kovacs. Introduction: Does Selling in May make sense? "Sell in May and go away." This Wall Street adage, with roots going back to 18th century England, has somehow endured the test of time. I've always been fascinated by these seasonal shifts and trends in the market. The original phrase was "Sell in May and go away and come back on St. Leger's day." St. Leger's day usually lands somewhere in the middle of September. The idea was that British investors should sell their shares to ...

PALM BEACH, Fla., May 24, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The pancreatic cancer market encompasses the pharmaceutical and healthcare sectors dedicated to addressing the prevention, diagnosis, and treatment of pancreatic cancer, a particularly aggressive and often fatal form of cancer affecting the pancreas. With its low survival rates and limited treatment options, pancreatic cancer remains a significant focus of medical research and development efforts. A recent report from BioSpa ...

EonerenIntroduction Some people on Wall Street are so powerful that whenever they are interviewed, people drop everything to hear what they have to say. One of these people is JPMorgan (JPM) CEO Jamie Dimon, who has a reputation as one of the best banking CEOs in modern history. Since January 1, 2000, his bank has returned 681%, beating the S&P 500 by roughly 220 points. That's a huge deal as it includes the Great Financial Crisis, the pandemic, and last year's banking woes. Data by YChartsWith that sai ...

-   Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)NORTH CHICAGO, Ill., May 23, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ: LABP). With the completion of the acquisition, Landos is now part of AbbVie.Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a memb ...

Biotech is one of the most exciting industries to invest in right now. Companies have drugs on the market worth billions and continue to strive to produce the newest and best treatments in modern medicine. Some biotech companies can face volatility as their popularity largely depends on pipeline updates. But some have proven more resilient than others.These three biotech stocks are some of the sector’s most consistently performing stocks. They produce medicines in both the pharma and biotech classes. Despit ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style ...

This company offers growth, high yield, and dividend growth.When it comes to investing, I often look for companies that generate strong amounts of free cash flow (FCF), and companies that can grow their FCF. One company that has proven that over the years is AbbVie (ABBV -0.99%). I often refer to it as The Investor's Trifecta, offering growth potential, high yield, and solid dividend growth.Check out this short video to learn more, consider subscribing to the channel, and check out the special offer in the ...